Skip to main content

Yeaman Kevin J's Form 4 filing

Dolby Laboratories, Inc. (DLB) · filed Nov 24, 2023

Accession no.
0001209191-23-056594
Filed
Nov 24, 2023
Trade date
Nov 21, 2023
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.83M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Yeaman Kevin JCIK 0001200469Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 21, 2023Class A Common StockMOption exerciseAcquired+45,150$42.98+$1,940,54797,029Indirect
Nov 21, 2023Class A Common StockSSaleDisposed−9,030$83.98F1−$758,339.487,999Indirect
Nov 21, 2023Class A Common StockSSaleDisposed−36,120$85.00−$3,070,20051,879Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 21, 2023Class A Common StockMOption exerciseDisposed−45,150$0.00$018,306Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares were sold in multiple transactions at prices ranging from $83.45 to $84.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

Remarks

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 28, 2022 which was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) in effect at the time of adoption.

Read the full filing on SEC EDGAR (opens in a new tab)